H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36

Moomoo NewsJan 22 10:31 ET

Leerink Partners Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $27

Moomoo NewsJan 13 13:31 ET

4D Molecular Therapeutics Is Maintained at Outperform by Leerink Partners

Dow JonesJan 13 11:23 ET

Morgan Stanley Maintains Underweight on 4D Molecular Therapeutics, Lowers Price Target to $6

BenzingaJan 13 11:16 ET

H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36

Moomoo NewsJan 13 07:34 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaJan 13 07:02 ET

HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

BenzingaJan 13 07:01 ET

Barclays Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)

TipRanksJan 12 08:28 ET

BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $42

Moomoo NewsJan 11 11:31 ET

BMO Capital Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating, Cuts Target Price to $15

Moomoo NewsJan 10 18:32 ET

4D Molecular Therapeutics Analyst Ratings

BenzingaDec 18, 2024 07:52 ET

BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $46

Moomoo NewsDec 18, 2024 07:31 ET

Morgan Stanley Initiates 4D Molecular Therapeutics(FDMT.US) With Sell Rating, Announces Target Price $8

Moomoo NewsNov 21, 2024 05:31 ET

Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $39

Moomoo NewsNov 14, 2024 17:32 ET

4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesNov 14, 2024 16:55 ET

RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating

Moomoo NewsNov 14, 2024 07:34 ET

H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36

Moomoo NewsNov 14, 2024 06:31 ET

Promising Pipeline Developments and Expanding Opportunities Lead to Buy Rating for 4D Molecular Therapeutics

TipRanksNov 14, 2024 06:19 ET

Barclays Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $45

Moomoo NewsNov 14, 2024 05:34 ET

Barclays Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

TipRanksNov 14, 2024 04:54 ET